Evaluating the ability of zoledronic acid to reduce the rate of subsequent osteoporotic fractures after a hip fracture

Trial Profile

Evaluating the ability of zoledronic acid to reduce the rate of subsequent osteoporotic fractures after a hip fracture

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2012

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Bone resorption; Fracture; Osteoporosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HORIZON-RFT
  • Most Recent Events

    • 01 May 2012 Actual end date changed from Nov 2006 to Feb 2007 as reported by ClinicalTrials.gov.
    • 01 Sep 2011 Results published in Osteoporosis International.
    • 19 Oct 2010 Results relating to quality of life presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top